CGH-LiNASH

UnknownPhase 3

Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults

Lead sponsor

Changi General Hospital

Assets

GLP-1 / incretin class catch-all / Liraglutide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Bariatric Surgery, MASH / NAFLD / liver fibrosis, Obesity / overweight

Eligibility highlights

•BMI ≥27.5•HbA1c ≤8%

Primary endpoint

•Improvement in NASH (ALT, change, AST, change, Liver fat content, change)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02654665

Org study IDCGH-LiNASH

Timeline

Milestones

Study first posted2016-01-13estimated

Last update posted2018-01-30actual

Study start2014-03 (month precision)

Primary completion2017-12actual (month precision)

Study completion2018-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all Liraglutide

Who this study enrolls

Bariatric SurgeryMASH / NAFLD / liver fibrosisObesity / overweight

Who can enroll

Minimum age21 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Body mass index > 27.5 kg/m2

•Waist circumference (WC) > 90 cm (male) or > 80 cm (female)

•Diagnosis of NASH based on Liver Function Test Results ,Ultrasound Hepato-Biliary System (HBS) findings and / or Liver Biopsy

•HbA1c < 8%* *Subjects in the bariatric surgery arm will not need to fulfil this criterion.

Exclusion criteria

•Currently using insulin-sensitising agents (metformin, pioglitazone), weight loss medication (orlistat, phentermine). Patients taking any of these drugs will require a three month washout period before enrolment.

•Pregnancy

•Significant cardiovascular or respiratory disease

•Renal impairment with eGFR < 60 ml/min

•Hepatitis B or C carrier, liver disease other than NAFLD

•History of pancreatitis

•Personal or family history of multiple endocrine neoplasia type 2 or thyroid carcinoma

•Untreated hypothyroidism or hyperthyroidism

•Current psychiatric illness

•Cardiac pacemaker, metallic prosthetic heart valves and other contraindications to MRI scan

•Current smoker

•Alcohol intake ≥ 14 units/week

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

MASH / liver

1 endpoint

Primary/protocol endpoint/low confidence

Improvement in NASH

Time frame:12 months

change from baseline, improvement

componentsALT, change, AST, change, Liver fat content, change

SNOMED 442685003

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Liver international : official journal of the International Association for the Study of the Liver2019 May (month)PMID30721572doi:10.1111/liv.14065via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.